These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 9720464)
1. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens. Wise R; Andrews JM J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. Morrissey I; Robbins M; Viljoen L; Brown DF J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996 [TBL] [Abstract][Full Text] [Related]
3. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN; J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Blondeau JM; Vaughan D; Laskowski R; Borsos S; Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615 [TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis. Kitzis MD; Goldstein FW; Miegi M; Acar JF J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333 [TBL] [Abstract][Full Text] [Related]
6. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Thornsberry C; Ogilvie P; Kahn J; Mauriz Y Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Sahm DF; Brown NP; Thornsberry C; Jones ME Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467 [TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000. Koeth LM; Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Appelbaum PC Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765 [TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010]. Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967 [TBL] [Abstract][Full Text] [Related]
10. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572 [TBL] [Abstract][Full Text] [Related]
11. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group. Blondeau JM; Suter M; Borsos S J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568 [TBL] [Abstract][Full Text] [Related]
12. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158 [TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. Casellas JM; Gilardoni M; Tome G; Goldberg M; Ivanovic S; Orduna M; Dolmann A; Ascoli M; Ariza H; Montero JM J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336 [TBL] [Abstract][Full Text] [Related]
14. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007]. Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709 [TBL] [Abstract][Full Text] [Related]
16. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China. Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692 [TBL] [Abstract][Full Text] [Related]
18. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens]. Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of fluoroquinolones against common respiratory pathogens. Aydemir S; Tunger A; Cilli F West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812 [TBL] [Abstract][Full Text] [Related]
20. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Jones RN; Fritsche TR; Sader HS; Stilwell MG Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]